Partner
Justin Hasford has experience in all areas of intellectual property law. His practice focuses on complex patent litigation at the trial and appellate levels on behalf of pioneer pharmaceutical companies. He has particular experience with cases arising from Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman Act. Justin also has litigated antitrust cases and business method patent cases.
Recognized as a Global Leader by Intellectual Asset Management's Strategy 300 and as a Next Generation Lawyer by The Legal 500 U.S. for patent litigation, Justin counsels clients on issues of infringement, validity, enforceability, antitrust, unfair competition, licensing, due diligence, and IP portfolio management. He has extensive experience advising clients regarding the interplay between patent and regulatory laws, including Orange Book listing of patents for drugs approved by the Food and Drug Administration (FDA).
Justin regularly speaks on the protection of U.S. intellectual property rights. He has also successfully represented a variety of low-income clients on a pro bono basis.
NOTE: No aspect of these rankings has been approved by the Supreme Court of New Jersey. Further information on methodologies is available via these links.
Senju Pharmaceutical Co.; Bausch + Lomb v. Lupin Ltd.
Secured a permanent injunction against generic defendants on behalf of Senju and Bausch + Lomb in Hatch-Waxman patent infringement litigation concerning multiple ANDAs for generic versions of Prolensa®.
1:14-cv-00667, -04149; 1:15-cv-00335; 1:16-cv-01097, D.N.J., Judges Goodman, Shipp, Simandle, Williams
Valeant Pharmaceuticals Int’l, Inc. v. Actavis Laboratories FL, Inc.
Represented Bausch Health Companies (f/k/a Valeant), Salix and Progenics—the innovators and patent owner—in this Hatch-Waxman infringement action in the District of New Jersey. A bench trial was held, and the presiding judge issued an 83-page opinion upholding the validity of the asserted patent claims and finding those claims infringed, thereby entering judgment in favor of plaintiffs through the life of the patents, extending through 2030.
2:16-cv-09038, D.N.J., Judges Chesler, Waldor
BioDelivery Sciences International, Inc. et al. v. Alvogen PB Research & Development LLC et al.
1:18-cv-01395, D. Del., Judge Connolly
Eli Lilly & Co. v. Wockhardt Ltd.
Represented Eli Lilly in Hatch-Waxman patent infringement litigations against several ANDA filers seeking FDA approval to market generic versions of Eli Lilly's Cymbalta®. The S.D. Indiana entered judgment before trial in favor of Eli Lilly and against all the ANDA filers on all issues, resulting in orders and judgment maintaining Cymbalta's® market exclusivity through the end of its patent life.
1:08-cv-01547, S.D. Ind., Judges Baker, Lawrence, Pratt
Total Rebuild Inc. v. PHC Fluid Power, LLC
6:15-cv-01855, W.D. La., Judge Doughty
Salient Systems Corporation v. Hawk Technology Systems LLC et al.
1:20-cv-01558, D. Del., Judge Connolly
Event
Recent Court Decisions in the Life Sciences Recent Court Decisions in the Life Sciences
May 22, 2024
Webinar
At the PTAB Blog
Petitioners Fail on Inherency but Prevail on Obviousness Petitioners Fail on Inherency but Prevail on Obviousness
February 9, 2024
Event
Inducement to Infringe in Hatch-Waxman Litigation: Strategies for Patent Drafting, Prosecution, and Litigation Inducement to Infringe in Hatch-Waxman Litigation: Strategies for Patent Drafting, Prosecution, and Litigation
December 14, 2023
Webinar
Event
Center for Intellectual Property x Innovation Policy Fall Conference Center for Intellectual Property x Innovation Policy Fall Conference
October 12-13, 2023
Arlington
Award/Ranking
Eleven Finnegan Attorneys Named to the 2024 IAM Strategy 300 List
Eleven Finnegan Attorneys Named to the 2024 IAM Strategy 300 List
August 14, 2024
IAMCommentary
3 Takeaways from Revived Obviousness Case On J&J Patent 3 Takeaways from Revived Obviousness Case On J&J Patent
April 17, 2024
Law360Award/Ranking
10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List 10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List
October 5, 2023
Intellectual Asset ManagementMedia Mention
Litigator of the Week Runners-Up and Shout Outs: Castle Retail Group Litigator of the Week Runners-Up and Shout Outs: Castle Retail Group
February 24, 2023
The AmLaw Litigation DailyPress Release
Finnegan Victory for BioDelivery Sciences International in ANDA Case Affirmed Finnegan Victory for BioDelivery Sciences International in ANDA Case Affirmed
December 29, 2022
Media Mention
Del. Judge Upholds Claims in Opioid Drug IP But Axes Others Del. Judge Upholds Claims in Opioid Drug IP But Axes Others
December 20, 2021
Law360Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.